Alcohol can increase the risk of dizziness, drowsiness, and liver strain when combined with duloxetine. It is safest to limit alcohol consumption and discuss any regular intake with your prescriber.
In the UK, duloxetine tablets are typically white, round or oblong, and bear imprint codes that vary by manufacturer (e.g., “C 20” for 20 mg). Inactive ingredients may include lactose, maize starch, and magnesium stearate.
Duloxetine is not a controlled substance and is not screened for in standard occupational drug-testing programmes. However, some sports anti-doping agencies list it as a prohibited substance in certain contexts; athletes should verify with their governing body.
Because duloxetine can cause dizziness, sleep disturbances, or impaired concentration, individuals in safety-critical roles should be assessed for fitness to work after dose initiation and during dose adjustments.
Unlike selective serotonin reuptake inhibitors (SSRIs) that target only serotonin, duloxetine also increases norepinephrine levels, which can provide additional benefit for pain syndromes and certain anxiety presentations.
Duloxetine was first synthesised in the 1990s by Eli Lilly and received MHRA approval in 2002 for major depressive disorder. Subsequent extensions of indication have expanded its use into neuropathic pain and fibromyalgia.
Duloxetine tablets are not scored and should be swallowed whole. Splitting may result in uneven dosing and altered absorption.
Duloxetine is metabolised mainly in the liver; rare cases of liver injury have been reported. Monitoring liver enzymes helps detect early signs of hepatic stress.
Generic duloxetine contains the same active ingredient and must meet the same bio-equivalence standards as the branded product, ensuring comparable efficacy and safety.
Pricing varies by manufacturer, dosage strength, and whether the patient qualifies for NHS prescription exemption. Generic formulations are typically less expensive than branded versions.
Duloxetine is an antidepressant and neuropathic pain medication that belongs to the serotonin-noradrenaline reuptake inhibitor (SNRI) class. It is supplied as oral pill tablets in strengths of 20 mg, 30 mg, 40 mg, and 60 mg. In the United Kingdom it is a prescription-only product (Rx) authorised by the Medicines and Healthcare products Regulatory Agency (MHRA) and is marketed by several manufacturers under brand names such as Cymbalta® and others.
Duloxetine blocks the re-uptake of the neurotransmitters serotonin and norepinephrine at nerve terminals. By increasing the concentration of these chemicals in the synaptic cleft, it helps to normalise mood, pain perception, and other central nervous system functions.
Duloxetine is approved by the MHRA for the following adult indications:
It is prescribed based on clinical assessment, and the choice of dose depends on the specific condition and patient response.
Some peer-reviewed studies and clinical guidelines have explored duloxetine for uses that are not officially approved in the UK:
Disclaimer: These applications are off-label and should only be considered under the direct supervision of a qualified healthcare professional after a thorough risk-benefit assessment.
If you are taking other medicines, supplements, or herbal products, inform your prescriber before starting duloxetine.
Standard dosing:
MDD, GAD, Fibromyalgia, Chronic Pain: Start with 30 mg once daily; increase to 60 mg once daily after at least one week if tolerated.
Diabetic Neuropathic Pain: Begin with 60 mg once daily (no titration required).
Special populations:
Elderly or hepatic impairment: Initiate at 20 mg once daily; may increase cautiously to 40 mg as tolerated.
Renal impairment (CrCl < 30 mL/min): Use with caution; no specific dosage adjustment is mandated, but monitor for accumulation.
Administration: Swallow the pill whole with a full glass of water. Do not crush or chew.
Missed dose: Take the missed tablet as soon as you remember, unless it is near the time of the next scheduled dose. Do not double the dose.
Overdose: Symptoms may include nausea, vomiting, drowsiness, tachycardia, and loss of coordination. Seek immediate medical attention; activated charcoal may be considered if presentation is early.
Discontinuation: Do not stop abruptly. Taper the dose gradually (e.g., reduce by 30 mg every 1-2 weeks) to minimise discontinuation syndrome, which can include dizziness, electric-shock sensations, and mood changes.
This article provides educational information about duloxetine and is not a substitute for professional medical advice. Treatment decisions, including the use of duloxetine for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes only and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
